- American City Business Journals•19 days ago
IsoRay (ISR), a Richland maker of implantable radioactive seeds for treating cancers, has been building up its staff and ramping up marketing under its new CEO. Since taking the reins earlier this year, CEO Thomas LaVoy has hired a vice president of sales and marketing, giving the company a senior manager for those areas, and hired a marketing firm to reshape the company’s image, said William Cavanagh, IsoRay’s chief operating officer. “Early on in the review process, it became clear to us that we needed to further invest in our business to generate future revenue growth,” LaVoy said in a statement in May. For the nine months ended March 31, 2016, IsoRay's revenue was $3.65 million, an 11.6 percent increase compared with $3.27 million for the year-earlier period.
- Capital Cube•last month
Click here to see latest analysisISRA VISION AG reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of ISRA VISION AG – Beta Systems Software AG, Nemetschek SE, USU Software AG, Triplan AG, ATOSS Software AG, Softing AG and GK Software AG (BSS-DE, NEM-DE, OSP2-DE, TPN-DE, […] (Read more...) The post ISRA VISION AG :ISR-DE: Earnings Analysis: Q2, 2016 By the Numbers : June 16, 2016 appeared first on CapitalCube.
|Bid||0.53 x 300|
|Ask||1.76 x 1000|
|52wk Range||0.55 - 1.68|
|Day's Range||0.80 - 0.84|
|Avg Vol (3m)||150,709|
As of 4:00 PM EDT. Market closed.